Regeneron reports 84-week Phase III data for Pasatru in adult FOP

Phase 3PasatruNeutral

AI Analysis

Summary

Regeneron Pharmaceuticals reported 84-week data from the Phase III OPTIMA trial evaluating Pasatru in adult patients with FOP. The article provides no details on efficacy outcomes or safety findings.

Clinical Trial Data

Phase

Phase III

Outcome Details

84-week Phase III OPTIMA trial data reported

Importance:6/10

Sentiment:

0.00

Phase IIIPasatruFOPRegeneronclinical trial data

Related Companies

$REGN

Read the original article

Published by Clinical Trials Arena on October 13, 2026 10:00 AM

Read Original